98%
921
2 minutes
20
We envision the Full-Body AI Agent as a comprehensive AI system designed to simulate, analyze, and optimize the dynamic processes of the human body across multiple biological levels. By integrating computational models, machine learning tools, and experimental platforms, this system aims to replicate and predict both physiological and pathological processes, ranging from molecules and cells to tissues, organs, and entire body systems. Central to the Full-Body AI Agent is its emphasis on integration and coordination across these biological levels, enabling analysis of how molecular changes influence cellular behaviors, tissue responses, organ function, and systemic outcomes. With a focus on biological functionality, the system is designed to advance the understanding of disease mechanisms, support the development of therapeutic interventions, and enhance personalized medicine. We propose two specialized implementations to demonstrate the utility of this framework: (1) the metastasis AI Agent, a multi-scale metastasis scoring system that characterizes tumor progression across the initiation, dissemination, and colonization phases by integrating molecular, cellular, and systemic signals; and (2) the drug AI Agent, a system-level drug development paradigm in which a drug AI-Agent dynamically guides preclinical evaluations, including organoids and chip-based models, by providing full-body physiological constraints. This approach enables the predictive modeling of long-term efficacy and toxicity beyond what localized models alone can achieve. These two agents illustrate the potential of Full-Body AI Agent to address complex biomedical challenges through multi-level integration and cross-scale reasoning.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407623 | PMC |
We envision the Full-Body AI Agent as a comprehensive AI system designed to simulate, analyze, and optimize the dynamic processes of the human body across multiple biological levels. By integrating computational models, machine learning tools, and experimental platforms, this system aims to replicate and predict both physiological and pathological processes, ranging from molecules and cells to tissues, organs, and entire body systems. Central to the Full-Body AI Agent is its emphasis on integration and coordination across these biological levels, enabling analysis of how molecular changes influence cellular behaviors, tissue responses, organ function, and systemic outcomes.
View Article and Find Full Text PDFSci Robot
August 2025
Toyota Research Institute, Cambridge, MA, USA.
Humans use diverse skills and strategies to effectively manipulate various objects, ranging from dexterous in-hand manipulation (fine motor skills) to complex whole-body manipulation (gross motor skills). The latter involves full-body engagement and extensive contact with various body parts beyond just the hands, where the compliance of our skin and muscles plays a crucial role in increasing contact stability and mitigating uncertainty. For robots, synthesizing these contact-rich behaviors has fundamental challenges because of the rapidly growing combinatorics inherent to this amount of contact, making explicit reasoning about all contact interactions intractable.
View Article and Find Full Text PDFBMC Anesthesiol
July 2025
Department of Anesthesiology, Critical Care and Pain Medicine, NHO Kure Medical Center and Chugoku Cancer Center, 3-1 Aoyama-cho, Kure, 734-0023, Japan.
Background: Sugammadex, a neuromuscular blockade reversal agent, has a reported incidence of severe anaphylaxis of approximately 0.005% in Japan, typically occurring within 5 min of administration. However, detailed case reports describing the full clinical course and associated changes in monitoring parameters—such as vital signs, capnographic waveforms, and airway pressure—remain limited.
View Article and Find Full Text PDFInt Ophthalmol Clin
July 2025
Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA.
Immunoglobulin G4-related disease (IgG4-RD) comprises a spectrum of inflammatory conditions characterized by lymphoplasmacytic infiltration by IgG4+ plasma cells, resultant tumefactive lesions at various locations in the body, storiform fibrosis, and elevated serum IgG4 levels. IgG4-related ophthalmic disease (IgG4-ROD) can occur in isolation or in conjunction with systemic findings. The most common manifestations of IgG4-ROD are dacryoadenitis and eyelid edema, though patients may also have trigeminal nerve enlargement, extraocular muscle involvement, and other orbital soft tissue lesions and inflammation.
View Article and Find Full Text PDF